Kanya Rajangam, MD, PhD, NKarta Therapeutics, South San Francisco, CA, provides an overview of the challenges in developing cell therapies in liquid and solid tumors. Whilst chimeric antigen receptor (CAR) T-cell therapies have been successful in B-cell malignancies such as myeloma, safety and cost issues as a result of T-cell expansion remain a barrier to widespread adoption. Further research is additionally required to enable the approval of cell therapies in other indications such as solid tumors and other B-cell malignancies including acute myeloid leukemia (AML). This interview took place at Meeting on the Mesa 2021.